Literature DB >> 32678342

A new dawn for eosinophils in the tumour microenvironment.

Sharon Grisaru-Tal1, Michal Itan1, Amy D Klion2, Ariel Munitz3.   

Abstract

Eosinophils are evolutionarily conserved, pleotropic cells that display key effector functions in allergic diseases, such as asthma. Nonetheless, eosinophils infiltrate multiple tumours and are equipped to regulate tumour progression either directly by interacting with tumour cells or indirectly by shaping the tumour microenvironment (TME). Eosinophils can readily respond to diverse stimuli and are capable of synthesizing and secreting a large range of molecules, including unique granule proteins that can potentially kill tumour cells. Alternatively, they can secrete pro-angiogenic and matrix-remodelling soluble mediators that could promote tumour growth. Herein, we aim to comprehensively outline basic eosinophil biology that is directly related to their activity in the TME. We discuss the mechanisms of eosinophil homing to the TME and examine their diverse pro-tumorigenic and antitumorigenic functions. Finally, we present emerging data regarding eosinophils as predictive biomarkers and effector cells in immunotherapy, especially in response to immune checkpoint blockade therapy, and highlight outstanding questions for future basic and clinical cancer research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32678342     DOI: 10.1038/s41568-020-0283-9

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  171 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

Review 2.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

Review 3.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 4.  Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red".

Authors:  James J Lee; Elizabeth A Jacobsen; Sergei I Ochkur; Michael P McGarry; Rachel M Condjella; Alfred D Doyle; Huijun Luo; Katie R Zellner; Cheryl A Protheroe; Lian Willetts; William E Lesuer; Dana C Colbert; Richard A Helmers; Paige Lacy; Redwan Moqbel; Nancy A Lee
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

5.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity.

Authors:  M E Rothenberg; J Petersen; R L Stevens; D S Silberstein; D T McKenzie; K F Austen; W F Owen
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

6.  Association of the blood eosinophil count with hematological malignancies and mortality.

Authors:  Christen L Andersen; Volkert D Siersma; Hans C Hasselbalch; Hanne Vestergaard; Ruben Mesa; Peter Felding; Niels D F Olivarius; Ole W Bjerrum
Journal:  Am J Hematol       Date:  2015-01-16       Impact factor: 10.047

Review 7.  Functions of tissue-resident eosinophils.

Authors:  Peter F Weller; Lisa A Spencer
Journal:  Nat Rev Immunol       Date:  2017-09-11       Impact factor: 53.106

8.  Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.

Authors:  P D Collins; S Marleau; D A Griffiths-Johnson; P J Jose; T J Williams
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

9.  Localization of the guinea pig eosinophil major basic protein to the core of the granule.

Authors:  D M Lewis; J C Lewis; D A Loegering; G J Gleich
Journal:  J Cell Biol       Date:  1978-06       Impact factor: 10.539

Review 10.  Eosinophils: changing perspectives in health and disease.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Paul S Foster
Journal:  Nat Rev Immunol       Date:  2012-11-16       Impact factor: 53.106

View more
  45 in total

1.  Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice.

Authors:  Gang Cao; Hua Miao; Yan-Ni Wang; Dan-Qian Chen; Xia-Qing Wu; Lin Chen; Yan Guo; Liang Zou; Nosratola D Vaziri; Ping Li; Ying-Yong Zhao
Journal:  Acta Pharmacol Sin       Date:  2022-05-16       Impact factor: 6.150

Review 2.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 3.  The use of biologics in personalized asthma care.

Authors:  David Watchorn; Fernando Holguin
Journal:  Expert Rev Clin Immunol       Date:  2021-11-23       Impact factor: 4.473

4.  Epidemiology and blood parameter changes in Cushing's syndrome - a population-based study.

Authors:  Jessica Mangion; Miriam Giordano Imbroll; Sarah Craus; Josanne Vassallo; Mark Gruppetta
Journal:  Hormones (Athens)       Date:  2022-07-06       Impact factor: 3.419

Review 5.  Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

Authors:  Sharon Grisaru-Tal; Marc E Rothenberg; Ariel Munitz
Journal:  Nat Immunol       Date:  2022-08-24       Impact factor: 31.250

6.  Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth.

Authors:  Rachel A Cederberg; Sarah Elizabeth Franks; Brennan J Wadsworth; Alvina So; Lisa R Decotret; Michael G Hall; Rocky Shi; Michael R Hughes; Kelly M McNagny; Kevin L Bennewith
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

7.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

Review 8.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

Review 9.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

Review 10.  The Interplay between the Immune and the Endocannabinoid Systems in Cancer.

Authors:  Mariantonia Braile; Simone Marcella; Gianni Marone; Maria Rosaria Galdiero; Gilda Varricchi; Stefania Loffredo
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.